Clayton Antitrust Act

Type: Keyphrase

Name: Clayton Antitrust Act

View more in our other sites:

entertainment

2 articles

First Reported Feb 23 2010 - Updated Feb 23 2010 - 1 Documents

Market Report -- In Play (PPO)

Polypore Intl comments on FTC's initial decision and announces appeal Co announcd the following update and comment to the Federal Trade Commission's administrative complaint originally issued against it on Sept 9, 2008. As previously disclosed in the ... [Published Feb 23 2010 by Briefing.com via MSN Money]

Entities: Clayton Antitrust Act, Polypore International Inc, Administrative Law, Acquisition, Federal Trade Commission

First Reported Oct 16 2009 - Updated Oct 16 2009 - 1 Documents

Patent Reform: Reverse Payments

Most patent infringement lawsuits are resolved with an agreement for the accused infringer to pay money to the patent right-holder. Generic drug-maker challenges to pharmaceutical patents occasionally follow a different path – with the patent holder ... [Published Oct 16 2009 by Patent Law Blog (Patently-O)]

Entities: Patent, Patent Infringement, Infringement, Unlawful, Clayton Antitrust Act

Quotes

IBM says Neon breaches that barrier and has "no other commercially significant purpose than to circumvent the protection afforded by z OS." It also says - and this is a peach of a contorted argument - that when zPrime runs applications or middleware, all allegedly copyrighted works, on the...

IBM-Neon Fight Flares [Sys-Con Canada - Feb 20 2010]

More Content

sort by: Date \| Relevance
Fool's Errand -- By: Conrad Black [National Review - Mar 04 2010]
Market Report -- In Play (PPO) [Briefing.com via MSN Money - Feb 23 2010]
IBM-Neon Fight Flares [Sys-Con Canada - Feb 20 2010]
IBM-Neon Fight Flares [AJAX and RIA Journal - Feb 03 2010]
Apple Could Have Problems With Goog ... [Web Host Directory - Jul 10 2009]

Blogs

sort by: Date \| Relevance
Patent Reform: Reverse Payments [Patent Law Blog (Patently-O) - Oct 16 2009] Most patent infringement lawsuits are resolved with an agreement for the accused infringer to pay money to the patent right-holder. Generic drug-maker challenges ...